Tempus AI (NASDAQ:TEM) CAO Sells $306,341.75 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 6,175 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $306,341.75. Following the completion of the sale, the chief accounting officer owned 67,866 shares of the company’s stock, valued at approximately $3,366,832.26. This trade represents a 8.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Performance

Shares of Tempus AI stock traded up $5.40 during mid-day trading on Thursday, hitting $66.65. 20,103,049 shares of the stock were exchanged, compared to its average volume of 5,600,288. Tempus AI, Inc. has a 12 month low of $40.77 and a 12 month high of $104.32. The company has a 50-day simple moving average of $52.44 and a 200 day simple moving average of $51.21. The company has a market capitalization of $12.03 billion, a P/E ratio of -46.28 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.Tempus AI’s quarterly revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.22) earnings per share. Sell-side analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Guggenheim boosted their price target on shares of Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Needham & Company LLC restated a “buy” rating and set a $75.00 price target on shares of Tempus AI in a research report on Friday, July 31st. Weiss Ratings upgraded shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tempus AI currently has an average rating of “Hold” and a consensus price target of $65.69.

Hedge Funds Weigh In On Tempus AI

Institutional investors and hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. increased its position in Tempus AI by 1.5% in the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after buying an additional 162 shares during the last quarter. Truist Financial Corp raised its stake in shares of Tempus AI by 5.8% in the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock valued at $209,000 after buying an additional 194 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Tempus AI by 3.5% during the 4th quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company’s stock valued at $377,000 after buying an additional 219 shares during the last quarter. SeaCrest Wealth Management LLC lifted its position in shares of Tempus AI by 3.7% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock valued at $524,000 after buying an additional 229 shares during the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in shares of Tempus AI by 29.4% during the 4th quarter. Geneos Wealth Management Inc. now owns 1,100 shares of the company’s stock worth $65,000 after acquiring an additional 250 shares during the period. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.